Matheus Oliveira Do Nascimento

Dr. Matheus Oliveira Do Nascimento


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2024 in OBSERVATÓRIO DE LA ECONOMÍA LATINOAMERICANA
Verified
Journal Article
Open access
PDF file
VLValéria Maria Sousa Leitão
Valéria Maria Sousa Leitão
MLMarcos Valério Vieira Lyrio
Marcos Valério Vieira Lyrio
GVGabriela Vanini
Gabriela Vanini
CCCarolina Borges Cordeiro
Carolina Borges Cordeiro
MOMatheus Filipe Leitão De Oliveira
Matheus Filipe Leitão De Oliveira
MNMaria Do Desterro Soares Brandão Do Nascimento
Maria Do Desterro Soares Brandão Do Nascimento
Fungi have been recognized as a great source of bioactive metabolites with great medical and pharmaceutical applicability. The objective of this work was to produce a fungal extract from Rhizopus spp and identify the secondary metabolites obtained, followed by preparation of a microemulsion formulated with Rhizopus sp extract; characterizing its antioxidant and antimicrobial activity. Among the metabolites obtained, sorbitol, linoleic acid, oleic acid, palmitic acid, and stearic acid stand out. The formulated microemulsion proved to be an effective pharmacological presentation in preserving the metabolites obtained from the fungal extract, and also potentiating in relation to the extract, when comparing the antioxidant activity and antimicrobial action.

28 September 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MNMatheus Oliveira Do Nascimento
Matheus Oliveira Do Nascimento
LDLeandro de Sousa Dias
Leandro de Sousa Dias
AMAllan Kayk Sales Meneses
Allan Kayk Sales Meneses
SLSidney De Lima
Sidney De Lima
CMCarla Veron̂ica Rodarte De Moura
Carla Veron̂ica Rodarte De Moura
ACAndré Luis Menezes Carvalho
André Luis Menezes Carvalho
Background/Objectives: The increasing incidence of invasive fungal infections and the emergence of antifungal resistance have limited the effectiveness of conventional therapies against Candida spp. This study aimed to develop and optimize nanostructured lipid carriers (NLCs) containing fluconazole (FLC) and Riparin B (RIP) using a systematic Quality-by-Design (QbD) approach. Methods: The optimized NLCs were characterized by particle size, polydispersity index (PDI), zeta potential, DSC, and FTIR analyses. Molecular docking was used as a complementary exploratory approach to investigate possible interactions of RIP with representative components of the lipid matrix and with fungal resistance-associated proteins. Release profiles and antifungal activity against Candida spp. were also evaluated. Results: The optimized NLCs exhibited a mean particle size of 144.9 ± 2.25 nm, PDI of 0.153 ± 0.03, and zeta potential of −27.8 ± 1.81 mV. DSC and FTIR analyses supported the structural organization of the lipid matrix and the formation of an imperfect crystalline network, providing structural defects favorable for the incorporation of the active compounds. RIP exhibited more favorable predicted interactions than FLC within the specific lipid configuration evaluated, although these docking scores should not be interpreted as direct thermodynamic measurements of drug–lipid affinity or as quantitative predictors of encapsulation efficiency. Docking analyses with MdR1, CdR1, and CdR2 identified possible interactions of RIP with these resistance-associated proteins, providing a structural hypothesis that may contribute to understanding the potentiation of FLC activity. However, these computational results do not establish direct efflux-pump inhibition. Release profiles followed distinct kinetic regimes, consistent with matrix relaxation for RIP and Fickian diffusion for FLC. Although RIP alone did not exhibit relevant antifungal activity, its association with FLC potentiated FLC activity against Candida spp., while incorporation of the combination into NLCs produced a further enhancement, significantly reducing the minimum inhibitory concentration. Conclusions: These findings indicate that the optimized NLC platform can enhance the antifungal performance of the FLC–RIP combination and provide a formulation framework for further investigation of this co-delivery strategy.